Compare NERV & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NERV | TNXP |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.1M | 199.7M |
| IPO Year | 2014 | 2008 |
| Metric | NERV | TNXP |
|---|---|---|
| Price | $4.11 | $9.92 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | 358.2K | ★ 544.8K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,175,600.00 | $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $1.76 | $10.03 |
| 52 Week High | $12.46 | $69.65 |
| Indicator | NERV | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 35.99 |
| Support Level | $3.80 | N/A |
| Resistance Level | $4.59 | $13.18 |
| Average True Range (ATR) | 0.38 | 0.93 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 18.81 | 1.20 |
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.